Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Gain Therapeutics presented Phase 1b open-label extension data showing MDS-UPDRS motor scores remained stable over 12 months of rexaceract dosing in all 12 evaluable participants, with no clinically meaningful disease progression in Parkinson's disease. No new safety signals were observed, and treatment-emergent adverse events declined in the 9-month extension versus the initial 3-month period; participants in both high and low CSF GluSph baseline groups showed stabilization.
Key figures
- Drug Name
- rexaceract (GT-02287)
- Phase Of Trial
- Phase 1b
- Phase2 start
- 1Q27
- Dosing duration months
- 12
- Evaluable participants
- 12
- Clinically meaningful progression threshold
- approximately 6 points MDS-UPDRS Part II+III over a year
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.